Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Non-Current Debt (2016 - 2019)

NovaBay Pharmaceuticals (NBY) has disclosed Non-Current Debt for 3 consecutive years, with $1.1 million as the latest value for Q2 2019.

  • On a quarterly basis, Non-Current Debt changed N/A to $1.1 million in Q2 2019 year-over-year; TTM through Jun 2019 was $1.1 million, a N/A change, with the full-year FY2015 number at $1.7 million, changed N/A from a year prior.
  • Non-Current Debt was $1.1 million for Q2 2019 at NovaBay Pharmaceuticals, up from $524000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $3.1 million in Q1 2016 to a low of $524000.0 in Q2 2016.
  • A 3-year average of $1.6 million and a median of $1.4 million in 2015 define the central range for Non-Current Debt.